In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CAT/OGS merger withdrawn

Executive Summary

Monoclonal antibody company Cambridge Antibody Technology Group is acquiring fellow UK drug company Oxford GlycoSciences in a stock deal valued at approximately £114.6mm ($185.6mm). For every outstanding OGS share, CAT will pay 0.362 share of its own stock, currently worth £2.06 ($3.33), a 28% premium to OGS's market average. OGS shareholders will own about 35.7% of the combined company, which will be renamed.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies